31 Mar 2026 Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate Investors | Therapeutics
26 Mar 2026 Proposed Placing via an accelerated bookbuild and Subscription to raise approximately £10 million Investors
17 Mar 2026 Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference Investors | Therapeutics
16 Mar 2026 Avacta announces opening of Phase 1 trial for second pipeline asset, FAP-Exd (AVA6103) a sustained-release pre|CISION® exatecan peptide-drug conjugate Investors | Therapeutics
24 Feb 2026 Research & Development Spotlight Series, Episode 14 Investors | R&D Spotlights Series | Therapeutics
24 Feb 2026 Avacta’s pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis Investors | Therapeutics